Loading organizations...
§ Private Profile · Burlingame, CA, USA
Clinical-stage biopharmaceutical company developing immune-targeted therapies for cancer treatment, modulating the immune system.
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing immune-targeted therapies for cancer treatment, headquartered in Burlingame, California. The enterprise operates within the oncology and broader health technology sectors by engineering innovative pharmaceutical drugs designed specifically to modulate the human immune system to effectively fight various tumors. Operating as a publicly traded entity on the NASDAQ exchange under the ticker symbol CRVS, the firm primarily funds its clinical-stage drug development pipeline through public equity financing and standard biopharma development milestones. The organization targets its specialized therapeutic solutions toward oncology patients, advancing its proprietary medical technologies through rigorous clinical trials to address significant unmet medical needs in the current global healthcare landscape. Corvus Pharmaceuticals was officially established in 2014 by the experienced founding team of Richard A. Miller, Peter Thompson, and Joseph J. Buggy.
Corvus Pharmaceuticals has raised $75.0M across 1 funding round.
Corvus Pharmaceuticals has raised $75.0M in total across 1 funding round.
Corvus Pharmaceuticals has raised $75.0M in total across 1 funding round.
Corvus Pharmaceuticals's investors include Rock Springs Capital, Adams Street Partners, BlackRock, Cormorant Asset Management, Cowen Private Investments, Fidelity Management & Research Company, Jennison Associates, Novo Ventures, OrbiMed, Roche, Sphera Funds Management, T. Rowe Price Associates.
Corvus Pharmaceuticals has raised $75.0M across 1 funding round. Most recently, it raised $75.0M Series B in September 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 29, 2015 | $75M Series B | Rock Springs Capital | Adams Street Partners, BlackRock, Cormorant Asset Management, Cowen Private Investments, Fidelity Management & Research Company, Jennison Associates, Novo Ventures, OrbiMed, Roche, Sphera Funds Management, T. Rowe Price Associates | Announced |